CCLG funds a wide variety of research into childhood cancer.
We offer funds and grants to research communities to discover new treatment methods and help push the boundaries to find ways of curing cancer. We support biological research through the CCLG Tissue Bank to give us a better understanding of the nature of childhood cancer.
We rely on fundraising and donations to support our research work. Many of our research projects are supported by our Special Named Funds, which may be 'ringfenced' to support our work into a specific disease. Some examples of the research we have funded are shown below.
1) Interfant 06 clinical trial
Interfant 06 is an international collaborative clinical trial aimed at improving treatment for infants under one year of age with acute lymphoblastic or biphenotypic leukaemia. The trial opened to recruitment in the UK in 2008, and since then the trial has recruited well, with 61 patients currently recruited (as at May 2014), above the original expected target of 54. CCLG supported this trial with a two-year project grant.
As part of this latest clinical trial into Ewing's sarcoma, CCLG has funded some ‘biomarker’ studies, led by CCLG member Professor Sue Burchill of the Children’s Cancer Research Group at the Leeds Institute of Cancer and Pathology. These biological studies examine how biomarkers, or particular molecules in the blood can be used to choose and adapt treatment for patients.
A special type of scanning has shown promise for imaging rhabdomyosarcoma, in research funded by CCLG and undertaken by CCLG member Dr Bob Phillips and colleagues at the University of York. Young people with rhabdomyosarcoma are given several treatments including chemotherapy, radiotherapy and surgery. To plan the best treatment, a range of tests is needed, some of which require a general anaesthetic. The aim of this research was to find out if functional Imaging could replace some of the tests or provide extra useful information about a patient’s disease.
In 2012, CCLG was able to fund three novel research studies into childhood cancer, and we were able to do so again in early 2014. The studies all make use of samples from the CCLG Tissue Bank, a vital resource for childhood cancer researchers which ensures that sufficient tissue samples of these rare diseases are available to conduct meaningful research. The aim of the pilot grants is to enable researchers to obtain preliminary data that will lead onto more extensive research projects.
We are delighted to have been able to support an extension to the RMS 2005 clinical trial. The RMS 2005 trial is for children and young people under 21 years of age who have rhabdomyosarcoma which is a cancer affecting muscle and soft tissue. The funding from CCLG will allow the trial to continue to recruit patients for a longer period of time so that enough patients are recruited and the important research questions can be answered.